Ferdinandos Skoulidis

Trials

Studies that name Ferdinandos Skoulidis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:46 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05118854 · A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

  M.D. Anderson Cancer Center · active not recruiting · Lung Cancer · principal investigator
• Ph2
  NCT04173507 · Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  SWOG Cancer Research Network · completed · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
• Ph1/Ph2
  NCT03225664 · Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

  M.D. Anderson Cancer Center · active not recruiting · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
  R01CA272570 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $370,575 awarded in 2026
  Same name and institution; not confirmed by an ID
• Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
  R01CA279194 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $370,575 awarded in 2026
  Same name and institution; not confirmed by an ID
• Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy
  R01CA301423 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $669,540 awarded in 2026
  Same name and institution; not confirmed by an ID
• Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
  R01CA279452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $672,046 awarded in 2026
  Same name and institution; not confirmed by an ID
• Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
  R01CA262469 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $370,575 awarded in 2025
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT04173507
• Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
  R01CA155196 · NCI · YALE UNIVERSITY · PI Roy S Herbst, Vassiliki Papadimitrakopoulou · fiscal years 2011 to 2015
  Named on NCT03225664